Knowledge Hub

Critical Outcome Technologies Inc. - Product Pipeline Review - 2016

Press Release   •   Nov 29, 2016 04:42 EST has recently announced the addition of a market study “ Critical Outcome Technologies Inc. - Product Pipeline Review - 2016 ”, is a comparative analysis of the global market.

Critical Outcome Technologies Inc. - Product Pipeline Review - 2016


Global Markets Directs, Critical Outcome Technologies Inc. - Product Pipeline Review - 2016, provides an overview of the Critical Outcome Technologies Inc.s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Critical Outcome Technologies Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


- The report provides a snapshot of the pipeline therapeutic landscape of Critical Outcome Technologies Inc.

- The report provides overview of Critical Outcome Technologies Inc. including its business description, key facts, and locations and subsidiaries

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report assesses Critical Outcome Technologies Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report features Critical Outcome Technologies Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Download The sample Copy Of This Report:

Reasons to buy

- Evaluate Critical Outcome Technologies Inc.s strategic position with total access to detailed information on its product pipeline

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Critical Outcome Technologies Inc.

- Identify potential new clients or partners in the target demographic

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Critical Outcome Technologies Inc.s pipeline depth and focus of pipeline therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Content

Table of Contents 2

List of Tables 4

List of Figures 4

Critical Outcome Technologies Inc. Snapshot 5

Critical Outcome Technologies Inc. Overview 5

Key Facts 5

Critical Outcome Technologies Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Critical Outcome Technologies Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Critical Outcome Technologies Inc. - Pipeline Products Glance 11

Critical Outcome Technologies Inc. - Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Critical Outcome Technologies Inc. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Critical Outcome Technologies Inc. - Drug Profiles 14

COTI-2 - Drug Profile 14

Product Description 14

Mechanism Of Action 14

R&D Progress 14

COTI-219 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

COTI-4 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

COTI-58 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Small Molecule for MRSA Infection - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Small Molecules for Acute Myelocytic Leukemia - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecules for Small Cell Lung Cancer - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules to Antagonize VEGF-R and PDGF-R for Multiple Sclerosis - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Small Molecules to Inhibit Angiogenesis for Undisclosed Indication - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Disclaimer 25